hPCSK9

Fig.1 Detection of human PCSK9 (A) and mouse PCSK9(B) expression in serum of WT C57BL/6 mice and HO hPCSK9 mice by ELISA. Mouse PCSK9 was exclusively detectable in wild-type C57BL/6 mice. Serum were collected from wild-type C57BL/6 mice (n=3, male, 6 weeks old) and HO hPCSK9 mice (n=3), and analyzed by ELISA.

Abbr.  HO, homozygous; WT, wild type; N.D. not dected.

Fig.2 Detection of the blood lipid index of (A) TG, (B) TC, (C) HDL-C and (D) LDL-C in chow diet-fed WT mice and HO hPCSK9 mice before treatment. (n=7-8, 6-week-old male mice).

Abbr. WT, wild type; HO, Homozygous; CD, chow diet.

Fig.3 Body weight in chow diet-fed and Evolocumab-treated HO hPCSK9 knockin mice (8 male mice in each group).

Abbr. HO, Homozygous; CD, chow diet.

Fig.4 Detection of the blood lipid index of (A) TG, (B) T-CHO, (C) HDL-C and (D) LDL-C in chow diet-fed and Evolocumab-treated HO hPCSK9 knockin mice. 

Blood lipids level of hPCSK9 mice before and after dosing were detected. Data were all normalized to control (8 male mice in each group. Mean ± SEM. *p < 0.05 and **p < 0.01 in Evolocumab group under t-test versus control).

Abbr. HO, Homozygous; CD, chow diet.

Fig.5 Liver weight-to-body weight ratio in chow diet-fed HO hPCSK9 knockin mice after 35 days of dosing (8 male mice in each group).

Abbr. HO, Homozygous; CD, chow diet.

Fig.6 Liver LDLR concentration in chow diet-fed HO hPCSK9 knockin mice after 35 days of dosing (8 male mice in each group, Mean±SEM, t-test, *p<0.05).

Abbr. HO, Homozygous; CD, chow diet.